AU2001222986A1 - Dehydroascorbic acid formulations and uses thereof - Google Patents
Dehydroascorbic acid formulations and uses thereofInfo
- Publication number
- AU2001222986A1 AU2001222986A1 AU2001222986A AU2298601A AU2001222986A1 AU 2001222986 A1 AU2001222986 A1 AU 2001222986A1 AU 2001222986 A AU2001222986 A AU 2001222986A AU 2298601 A AU2298601 A AU 2298601A AU 2001222986 A1 AU2001222986 A1 AU 2001222986A1
- Authority
- AU
- Australia
- Prior art keywords
- dehydroascorbic acid
- acid formulations
- formulations
- dehydroascorbic
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 title 1
- SBJKKFFYIZUCET-UHFFFAOYSA-N Dehydroascorbic acid Natural products OCC(O)C1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-UHFFFAOYSA-N 0.000 title 1
- 235000020960 dehydroascorbic acid Nutrition 0.000 title 1
- 239000011615 dehydroascorbic acid Substances 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Anesthesiology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20587000P | 2000-05-19 | 2000-05-19 | |
| US60/205,870 | 2000-05-19 | ||
| PCT/US2000/041407 WO2001089520A2 (fr) | 2000-05-19 | 2000-10-20 | Formulations d'acide dehydroascorbique et leurs utilisations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001222986A1 true AU2001222986A1 (en) | 2001-12-03 |
Family
ID=22763983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001222986A Abandoned AU2001222986A1 (en) | 2000-05-19 | 2000-10-20 | Dehydroascorbic acid formulations and uses thereof |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1282416A2 (fr) |
| JP (1) | JP2004514650A (fr) |
| AU (1) | AU2001222986A1 (fr) |
| CA (1) | CA2408562A1 (fr) |
| WO (1) | WO2001089520A2 (fr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1749552A1 (fr) * | 2005-07-29 | 2007-02-07 | Neuropharma S.A. | Utilisation de la collismycine et de ses dérivés en tant qu'inhibiteurs du stress oxydatif |
| EP2262509A4 (fr) * | 2008-03-07 | 2012-02-22 | Lawrence Bernstein | Composés de gallium et procédés d utilisation pour traiter les maladies inflammatoires chroniques de l intestin |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| US9101537B2 (en) | 2008-07-25 | 2015-08-11 | Reven Pharmaceuticals, Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
| NL2004260C2 (en) * | 2010-02-18 | 2011-08-22 | Univ Amsterdam | Disinfectant composition and its use in dental treatment. |
| WO2012012682A2 (fr) | 2010-07-22 | 2012-01-26 | Zishan Haroon | Méthodes destinées à traiter ou à améliorer des maladies et à renforcer la performance comprenant l'utilisation d'une solution stabilisée par un dipôle magnétique |
| DK2680833T3 (en) * | 2011-03-04 | 2016-05-23 | Gruenenthal Gmbh | PARENTERAL SUBMISSION OF TAPENTADOL |
| US10531655B2 (en) | 2011-12-02 | 2020-01-14 | The Regents Of The University Of California | Reperfusion protection solution and uses thereof |
| CA2925546C (fr) | 2012-10-29 | 2022-06-14 | The University Of North Carolina At Chapel Hill | Methodes et compositions pour traiter des troubles du tissu mucosal |
| CN108289890B (zh) | 2015-12-02 | 2021-04-27 | 日本新药株式会社 | 含有2-{4-[n-(5,6-二苯基吡嗪-2-基)-n-异丙基氨基]丁氧基}-n-(甲磺酰基)乙酰胺的医药组合物 |
| US11602555B2 (en) | 2016-11-17 | 2023-03-14 | Renovion, Inc. | Treatment of respiratory tract diseases and infections with ascorbic acid compositions |
| RU2693627C2 (ru) * | 2017-11-03 | 2019-07-03 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
| MX2020005087A (es) | 2017-11-17 | 2020-08-13 | Renovion Inc | Composiciones de acido ascorbico estables y metodos de uso de las mismas. |
| JOP20200134A1 (ar) * | 2017-12-07 | 2022-10-30 | Reven Llc | تركيبات وطرق لمعالجة حالات أيضية |
| EP3852529A4 (fr) * | 2018-09-17 | 2021-10-27 | Smithers-Oasis Company | Composition et procédé pour améliorer la tolérance à la sècheresse de plantes |
| BR112021025105A2 (pt) * | 2019-06-12 | 2022-03-15 | Reven Ip Holdco Llc | Métodos e composições para melhorar os resultados de pacientes com câncer |
| WO2021183705A1 (fr) * | 2020-03-11 | 2021-09-16 | Siess Harold E | Détection et traitement de maladies virales et du cancer |
| CA3240818A1 (fr) | 2022-01-04 | 2023-07-13 | Edward J. Delaney | Solution aqueuse comprenant un sel de glutathion |
| CN115316375B (zh) * | 2022-08-15 | 2023-08-18 | 四川大学华西医院 | 一种用于腹部器官移植供体灌注的一体式穿刺灌注导管 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2845484A1 (de) * | 1978-10-19 | 1980-04-30 | Groening Ruediger | Verfahren zur erhoehung der biologischen verfuegbarkeit von arzneistoffen |
| GB2080681B (en) * | 1980-07-24 | 1985-07-10 | Miller Ercell L | Oral compositions |
| US5070085A (en) * | 1987-04-10 | 1991-12-03 | Oxycal Laboratories, Inc. | Compositions and methods for administering therapeutically active compounds |
| AT393221B (de) * | 1988-02-03 | 1991-09-10 | Leopold Pharma Gmbh | Mittel mit zerstoerender wirkung auf maligne tumore, verfahren zu dessen herstellung und praeparation zur anwendung in der therapie von krebskranken |
| US5021452A (en) * | 1989-01-09 | 1991-06-04 | The Board Of Regents Of The University Of Washington | Process for enhancing wound healing |
| US5281196A (en) * | 1992-05-22 | 1994-01-25 | Sultenfuss Thomas J | Skin treatment composition and method of use |
| US6262111B1 (en) * | 1997-05-21 | 2001-07-17 | Sloan-Kettering Institute For Cancer Research | Method for increasing the concentration of ascorbic acid in brain tissues of a subject |
| CA2290381A1 (fr) * | 1997-05-21 | 1998-11-26 | Sloan-Kettering Institute For Cancer Research | Procede permettant d'augmenter la concentration d'acide ascorbique dans les tissus cerebraux d'un individu |
| DE19935763B4 (de) * | 1999-07-27 | 2006-03-02 | Jenning, Volkhard, Dr. | Zusammensetzung eines Redoxsystems zur Stabilisierung von Retinoiden in Präparaten zur äußerlichen Anwendung |
| ATE401071T1 (de) * | 1999-08-30 | 2008-08-15 | Ester C Company | Verwendungen und zusammensetzungen für selektive krebs-chemotherapie |
-
2000
- 2000-10-20 CA CA002408562A patent/CA2408562A1/fr not_active Abandoned
- 2000-10-20 AU AU2001222986A patent/AU2001222986A1/en not_active Abandoned
- 2000-10-20 EP EP00986812A patent/EP1282416A2/fr not_active Withdrawn
- 2000-10-20 WO PCT/US2000/041407 patent/WO2001089520A2/fr not_active Ceased
- 2000-10-20 JP JP2001585764A patent/JP2004514650A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP1282416A2 (fr) | 2003-02-12 |
| WO2001089520A3 (fr) | 2002-09-12 |
| WO2001089520A2 (fr) | 2001-11-29 |
| JP2004514650A (ja) | 2004-05-20 |
| CA2408562A1 (fr) | 2001-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2002232492A1 (en) | Rapidly dispersing pharmaceutical composition comprising effervescent agents | |
| AU2001294814A1 (en) | Pumpcn compositions and uses thereof | |
| AU2001233738A1 (en) | Improved paste formulations | |
| AU7645701A (en) | Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides | |
| AU2002225855A1 (en) | Preparation of nanocrystallites | |
| AU2002351854A1 (en) | Ink formulations and uses thereof | |
| IL154031A0 (en) | Substituted sulfonylaminomethylbenzoic acid derivatives and preparation | |
| AU2001257326A1 (en) | Topical anesthetic/opioid formulations and uses thereof | |
| AU2001222986A1 (en) | Dehydroascorbic acid formulations and uses thereof | |
| AU2001287898A1 (en) | Pyrazolopyridines and pyrazolopyridazines as antidiabetics | |
| AU2001295657A1 (en) | Formulation containing wax-esters | |
| AU2001263839A1 (en) | Liquid formulations | |
| AU2001267707A1 (en) | Antiperspirant formulations | |
| AU2001248215A1 (en) | Cosmetically active composition | |
| AU2002214324A1 (en) | Medicinal compositions | |
| AU2001283344A1 (en) | Dermatological formulation | |
| AU2001290239A1 (en) | Medicinal composition | |
| AU2001235437A1 (en) | Isothiazolecarboxylic acid derivatives and their use as microbicides | |
| AU2001229439A1 (en) | Bioconjugates and uses thereof | |
| AU2001267693A1 (en) | Antiperspirant formulations | |
| AU4085201A (en) | Pharmaceutical composition | |
| AU2002212281A1 (en) | Anti-inflammatory active ingredients | |
| AU2002246659A1 (en) | Benzoylalkylindolepyridinium compounds and pharmaceutical compositions comprising such compounds | |
| AU4876701A (en) | Peptide derivatives and medicinal compositions | |
| AU4543500A (en) | Pharmaceutical compositions and uses |